Who are Ibrutinib combined with As2O3's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ibrutinib-combined-with-as2o3.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Ibrutinib combined with As2O3 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ibrutinib combined with As2O3 (Ibrutinib combined with As2O3) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: BTK inhibitor combined with arsenic compound. Area: Oncology.

phase 3 BTK inhibitor combined with arsenic compound BTK (Bruton's tyrosine kinase); As2O3 has multiple targets including PML-RARA fusion protein and mitochondrial pathways Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Ibrutinib combined with As2O3 (Ibrutinib combined with As2O3) — Peking University People's Hospital. Ibrutinib inhibits Bruton's tyrosine kinase (BTK) to block B-cell proliferation, while arsenic trioxide (As2O3) induces apoptosis and differentiation in leukemic cells through multiple pathways.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ibrutinib combined with As2O3 TARGET	Ibrutinib combined with As2O3	Peking University People's Hospital	phase 3	BTK inhibitor combined with arsenic compound	BTK (Bruton's tyrosine kinase); As2O3 has multiple targets including PML-RARA fusion protein and mitochondrial pathways

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (BTK inhibitor combined with arsenic compound class)

Peking University People's Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ibrutinib combined with As2O3 — Competitive Intelligence Brief. https://druglandscape.com/ci/ibrutinib-combined-with-as2o3. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab